Literature DB >> 28734547

Management of Hemostatic Disorders in Patients With Advanced Liver Disease Admitted to an Intensive Care Unit.

Ton Lisman1, William Bernal2.   

Abstract

Patients with liver diseases frequently acquire complex changes in their hemostatic system. Traditionally, bleeding complications in patients with liver disease were ascribed to these hemostatic changes, and liver diseases were considered as an acquired bleeding disorder. Nowadays, it is increasingly acknowledged that patients with liver diseases are in "hemostatic rebalance" due to a commensurate decline in pro- and anticoagulant drivers. Indeed, both thrombosis and bleeding may complicate liver disease. Such complications may be particularly worrisome in critically ill patients with liver disease. This review will outline knowns and unknowns in prediction, prevention, and treatment of bleeding and thrombosis in patients with liver disease admitted to an intensive care unit.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute-on-chronic liver failure; Anticoagulants; Bleeding; Cirrhosis; Fresh frozen plasma; Intensive care; Liver; Prothrombin time; Thromboelastography; Thrombosis

Mesh:

Year:  2017        PMID: 28734547     DOI: 10.1016/j.tmrv.2017.06.002

Source DB:  PubMed          Journal:  Transfus Med Rev        ISSN: 0887-7963


  2 in total

1.  Plasma levels of circulating DNA are associated with outcome, but not with activation of coagulation in decompensated cirrhosis and ACLF.

Authors:  Annabel Blasi; Vishal C Patel; Jelle Adelmeijer; Sarah Azarian; Fatima Aziz; Javier Fernández; William Bernal; Ton Lisman
Journal:  JHEP Rep       Date:  2019-06-28

2.  Mixed Fibrinolytic Phenotypes in Decompensated Cirrhosis and Acute-on-Chronic Liver Failure with Hypofibrinolysis in Those With Complications and Poor Survival.

Authors:  Annabel Blasi; Vishal C Patel; Jelle Adelmeijer; Sarah Azarian; Maria Hernandez Tejero; Andrea Calvo; Javier Fernández; William Bernal; Ton Lisman
Journal:  Hepatology       Date:  2019-10-24       Impact factor: 17.425

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.